secwatch.observer — SEC 8-K summary
======================================

Issuer:     Valion Bio, Inc. (VBIO)
CIK:        0001787740
Form:       8-K
Filed at:   2026-09-01T10:00:22+00:00
Accession:  0001683168-26-006848
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 1.01, 3.02, 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Valion Bio appoints Lisa Wolf President/COO, adds two directors, raises $7.7M from 3i
--------------------------------------------------------------------------------

- Lisa Wolf becomes President and COO, retains CFO role; former CEO Michael K. Handley has departed.
- Jared Malbin (Lucid Capital Markets COO) and Thomas Jensen (Allarity Therapeutics CEO) joined the board.
- Letter agreement with 3i: issued 100 Series B and 7,637 Series C preferred plus warrants for $7.737M; $1.5M cash to company.
- Warrants cover 1,053,969 shares at $3.62 exercise; $6.137M retained by 3i to satisfy overdue cash true-up.
- Lead asset Entolimod targets projected $7.8B Acute Radiation Syndrome market by 2032.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826006848/0001683168-26-006848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787740/000168316826006848/valion_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-26-006848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer